Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of metoprolol succinate plus trimetazidine in the management of angina pectoris in coronary artery disease
Abstract
Purpose: To investigate the efficacy of metoprolol succinate (MET) plus trimetazidine (TMZ) in the management of angina pectoris in coronary artery disease.
Methods: A total of 94 patients with coronary angina were assigned equally to study group (received MET plus TMZ in addition to conventional symptomatic treatment) and control group (received conventional symptomatic treatment such as statins, nitrates, and aspirin). Heart rate was measured by a pulse oximeter, while angina attacks were measured by electrocardiogram (ECG). Left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and left ventricular posterior wall end diastole (LVPWD) were measured by cardiac ultrasound. Enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of hypersensitive C-reactive protein (hs-CRP). Adverse reactions were self-reported.
Results: MET plus TMZ group produced significantly higher treatment responses for patients (95.74 %) than control group which received conventional medication (80.85 %, p < 0.05). Patients exhibited a significantly lower heart rate, fewer angina attacks, and a shorter duration of attacks after administration of MET plus TMZ compared to conventional medication (p < 0.05). MET plus TMZ treatment resulted in significantly higher LVEF, shorter LVEDD, and LVPWD than conventional treatment (p < 0.05). The study group exhibited a significantly milder inflammatory response indicated by lower serum hypersensitive C-reactive protein (hs-CRP) concentrations, and lower incidence of adverse events (4.26 ) compared to control group (17.02 %, p < 0.05).
Conclusion: MET plus TMZ provides significant treatment benefits for patients with angina pectoris in coronary artery disease, mitigates clinical symptoms and inflammatory responses, enhances cardiac function, and improves treatment safety by reducing risk of adverse events.
